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Abstract: The uridyl peptide antibiotics (UPAs), of which
pacidamycin is a member, have a clinically unexploited mode
of action and an unusual assembly. Perhaps the most striking
feature of these molecules is the biosynthetically unique 3’-
deoxyuridine that they share. This moiety is generated by an
unusual, small and monomeric dehydratase, Pac13, which
catalyses the dehydration of uridine-5’-aldehyde. Here we
report the structural characterisation of Pac13 with a series of
ligands, and gain insight into the enzymes mechanism
demonstrating that H42 is critical to the enzymes activity
and that the reaction is likely to proceed via an E1cB
mechanism. The resemblance of the 3’-deoxy pacidamycin
moiety with the synthetic anti-retrovirals, presents a potential
opportunity for the utilisation of Pac13 in the biocatalytic
generation of antiviral compounds.
Nucleic acids play a central role in nature and modified
nucleosides are present in a wide range of anti-viral, anti-
cancer drugs and antibiotics.[1] Though a variety of naturally
occurring nucleic acid analogues exist, few include modifica-
tions to the ribose or deoxyribose ring. The uridyl peptide
antibiotics (UPAs) pacidamycin, naspamycin, mureidomycin
and sansanmycin, attract much attention[2] with a clinically
unexploited mode of action[1] and an unusual biosynthetic
assembly.[3] Intriguingly, the (UPAs) contain a biosynthetically
distinct 3’-deoxyuridine that resembles the synthetic anti-
retrovirals such as stavudine 4, abacavir 5 (Figure 1) and the
cytotoxic natural product cordycepin 6, the biosynthesis of
which has not yet been determined.[4] A detailed mechanistic
understanding of the individual enzymes employed in the
generation of the 3’-deoxyuridine core is required in order to
facilitate their future biotransformative potential.
In pacidamycin 3, biosynthesis the 3’-deoxy moiety is
mediated by Pac13, an enzyme found to catalyze the key
dehydration of uridine-5’-aldehyde 1 to form 3’-deoxy-3’,4’-
didehydrouridine-5’-aldehyde 2. Previously proposed as
a dehydratase[5] investigations into the structure, kinetics
and mechanism of this unusual enzyme remained to be
performed. In stark contrast to most characterised dehydra-
tases, Pac13 is small (121 aa), monomeric, co-factor inde-
pendent and utilises a non-activated nucleoside, rather than
a free monosaccharide, as a substrate.[6] The biosynthetic
uniqueness coupled to the potential synthetic utility inspired
us to investigate Pac13s structure and mechanism. This is the
first mechanistic study of the formation of the 3’- deoxynu-
cleosides in natural product biosynthesis. We demonstrate
that not only is Pac13 unusually small, monomeric and
cofactor independent, but that it is also mechanistically
distinctive.
Dehydratases are important enzymes in primary and
secondary metabolism and have been shown to mediate
catalysis via a variety of mechanisms[7] including metal-
dependent, acid-base, radical[8] and covalent[9a] mechanisms
which we summarise in the Supporting Information (SI),
Figure 1. Medicinally relevant compounds containing 3’-deoxy-nucleo-
side moieties: A) biogenesis of the pacidamycin nucleoside motif:
Pac13 catalyses dehydration of uridine-5’-aldehyde 1 to form 3’-deoxy-
3’,4’-didehydrouridine-5’-aldehyde 2 ; B) pacidamycin, an uridyl peptide
antibiotic (highlighted: the pacidamycin nucleoside core, the character-
istic 3’-deoxy uridine); C) stavudine 4 and abacavir 5, widely used anti-
virals and cordycepin 6, cytotoxic natural product.
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Figure S15. All dehydratases studied so far that are involved
in carbohydrate processing, to the best of our knowledge,
have been shown to be large, multimeric and in general to
require co-factors (commonly metal ions or nucleotide) or
needing covalent interactions for catalysis. A handful of
dehydratases studied so far utilise a more unusual E1cb
mechanism, these include the well-studied dTDP-d-glucose
4,6-dehydratase RmlB[6a] and the UDP-GlcNAc 5,6-dehydra-
tase TunA,[6b] both nicotinamide-dependent (Figures S15 and
S16, SI p. 21). RmlB and TunB mediate an NAD+ assisted
oxidation of a hydroxy group within their nucleotide sub-
strates, followed by the enzymes mediation of an E1cb
dehydration to generate the respective enones, and a subse-
quent reduction of the resultant conjugatedC=C double bond
in the case of RmlB (Figure S16).[6a] 3-dehydroquinate
dehydratase I (DHQ I) is a dimeric enzyme which catalyses
the third step of the shikimate pathway in a variety of
organisms. It relies upon an essential Schiff base formation
(Figure S16) between the substrate and a conserved lysine for
catalysis that leads to an E1cb elmination.[9b]
Bioinformatic analysis of Pac13 using BLAST[10] and
HHpred,[11] reinforced Pac13s similarity to both metal
dependent and metal independent cupins,[12] including lyases
and isomerases (Tables S5–S7). Heterologous expression,
purification and crystallisation resulted in Pac13 wt crystals
that diffracted to 1.55 . Solution of the structure required
the preparation of the seleno-methionine derivative (SeMet-
Pac13) and demonstrated that the enzyme was indeed a cupin
(Figure 2). Pac13 is the only monomeric, metal-free cupin
dehydratase characterised to date (Table S8). Cupins gener-
ally occur as components of multimeric complexes and are
frequently accompanied by metal ions,[12b] in contrast Pac13 is
small, discrete and metal independent. Comparison of the
Pac13 coordinates with the PDB archive using the Dali
server[13] (Table S6) revealed that the two closest homologues
are cupins of non-assigned function, while the third is the
lyase KdgF[14] (PDB: 5fpx, Z-score 13.4, RMSD 2.1). KdgF is
a dimeric, cupin (Figure S18) requiring a M2+ for the
conversion of 4,5-unsaturated galacturonate (DGalUA) to 5-
keto-4-deoxyuronate (DKI), a reaction distinct to Pac13s
chemistry.
Whilst the cupin fold[12] is common for isomerases and
epimerases (eg RmlC[15]) as shown in the CATH database
(Figure S18) it is not common for lyases and ectoine synthase
(EtcC) is the only other cupin shown function as a dehydra-
tase, (Table S8, Figure S21). Perhaps such dehydratase activ-
ity will be seen to be very rare for cupins as the open b-barrel
does not assist in the protection of the product from water.
EtcC is dimeric and Fe2+ dependent, catalysing the formation
of ectoine by ring closure of the substrate N-g-acetyl-l-2,4-
diaminobutyric acid.
The open active site of wt Pac13 did not allow us to locate
the substrate binding site with confidence. Initial soaks with
uridine-5’-aldehyde 1, the natural substrate, were problematic
due to both turnover and the inherent instability of this
molecule. In order to overcome this problem we used
substrate analogues, uridine 7 and uridine 5’-uronic acid 8,
which enabled us to obtain liganded complexes of the enzyme,
providing the first clues of the location and structural
Figure 2. A) Crystal structure of Pac13 (PDB: 5OO5), refined as the
monomer to 1.55 , MolProbity score of 96%. Cartoon representation
of Pac13 with uridine 5’-uronic acid 8. B) Active site “pocket” of Pac13
with uridine 5’-uronic acid 8. Residues K16, L21, F103 and the ligand
are shown as stick representation. Pac13 is shown as cartoon and
surface. C) Active site of Pac13 with uridine 5’-uronic acid 8. The active
site residues Y89, Y55, K16, E108 and F103 and their distances from
the ligand functional groups are shown. V36 and L96 are also shown.
D) Compounds that were successfully used for crystal soaks: uridine 7,
uridine 5’-uronic acid 8.
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determinants of the active site (Figure 1). Both ligands
occupied the same binding pocket in their respective co-
crystal structures (Figure S20). Comparison of the apo- and
ligand-bound structures revealed that small movements in
residues such as K16, F103 and L21 create a pocket that
encloses the ribose ring of the substrate analogues but leave
one side of the uracil group solvent exposed (Figure 1).
Within the ribose pocket, the 5’ oxygen lies almost equidistant
(2.5–2.7 ) between Y55 and Y89, with a slightly shorter
distance to Y89, whereas the 4’ proton and 3’ hydroxy are 2.7–
3  from H42.
This leaves the 2’ hydroxy of the ribose ring coordinated
by the side chains of K16 and E108. In contrast to this
extensive network of direct polar interactions the uracil ring
makes a single H-bond to K16 at the lip of the active site, with
more Van der Waals (L21, V34, V99) and p-stacking
interactions (F103) characterising recognition of this part of
the substrate. Notably, lipophilic residues L97 and V36 border
the active site, creating a hydrophobic environment and
perhaps sheltering the substrate or dehydrated product from
attack from water. Pac13s substrate-binding site is distinct to
the active site environment of the most well characterised
cupin isomerases, such as RmlC[15] (Scheme S1), suggesting
a unique mechanism.
The observed electronic environment in the active site
caused us to disfavour series of mechanisms. An E2 mecha-
nism is unlikely; the substrates stereochemistry prevents the
required antiperiplanar relationship between the proton
being abstracted and the exiting hydroxy. It is unlikely that
an E1 mechanism (Scheme 1B) operates, as there is no highly
acidic residue proximal to the 3’ hydroxy group that could
assist the stabilisation of a carbocation. A dehydroquinase
type I mechanism (Figure S16) can be eliminated as the
possibility of a covalent lysine linkage does not exist.
Furthermore a radical mechanism (Scheme 1C) could be
excluded due to the absence of a metal ion or prosthetic
group. An E1cB mechanism can be postulated from the
structure to be likely (Scheme 1A): in the first step, H42 could
act as base extracting the activated 4’ proton, creating an
enolate 10. The oxyanion could then be stabilised by hydro-
gen bonding by Y55 and Y89, and the protonated H42 could
then act as the acid, donating a proton to 3’ hydroxy group of
the substrate and thus generating a better leaving group.
Alternatively, as informed by the crystal structures of the
Pac13 complex, E108 could play a dual role: substrate binding
and acting as the active-site acid, through a coordinated water
molecule (Figure S19). Electrons moving from the enolate
could lead to water elimination at 3’ position and generation
of the desired product. Residues F103 and K16 could simply
be involved in the orientation and binding of the substrate,
rather than in catalysis. This proposed mechanism is perhaps
closest to the E1cb mechanism postulated to be utilised by
DHQ II, a dodecameric enzyme with a flavodoxin-like fold[9b]
(Scheme 2), but distinctive with Y89 and Y55 potentially
acting to stabilise the enolate anion and H42 implicated as
possibly playing the role the role of both acid and base.
To probe Pac13 function, the reaction of Pac13 with
uridine-5’-aldehyde 1 was monitored by LC-MS. A species
with m/z 225, corresponding to the 3’-deoxy-3’,4’-didehy-
drouridine-5’-aldehyde 2 was detected. No conversion could
be seen in enzyme free controls. In aqueous conditions,
1 exists completely as its hydrate form.[3c] Next, we followed
the reaction by 1H NMR and observed the disappearance of
the 4’ proton multiplet at 4.0 ppm. The characteristic 3’ proton
could be seen to shift downfield, appearing as a doublet of
doublets at 5.4 ppm, consistent with generation of an olefinic
bond, and enabling reaction monitoring. Unlike other dehy-
dratase-mediated reactions that exist in equilibrium,[7] we
demonstrate here that the Pac13-catalysed dehydration of
uridine-5’-aldehyde reaches completion. However, rapid
abstraction of the 4’ proton in comparison to the depletion
of other substrate protons such as H5 and H6, indicative of an
Scheme 1. Proposed mechanism for Pac13-mediated dehydration of
uridine-5’-aldehyde 1 to to form 3’-deoxy-3’,4’-didehydrouridine-5’-alde-
hyde 2. Initially speculated Pac13-mediated dehydratase mechanisms:
A) E1cB mechanism; B) carbocation formation; C) radical formation.
Scheme 2. Proposed E1cb mechanism for DHQ II, depicting Tyr28
acting as base to catalyse enolate formation, with the enolate being
stabilised by hydrogen bonding to regions oft he peptide backbone, via
a bridging water molecule. Figure adapted from Ref. [9b].
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E1Cb mechanism, was not observed (Figure S24-5, SI p. 33).
COSY and HSQC NMR of the enzymatic preparation
allowed us to confirm the structure of the expected product.
The optimal conditions for Pac13 activity were then exam-
ined. NADH, NADPH, MgCl2 were found not to be required.
Based on extensive crystallographic and biochemical analysis,
including enzymatic assay in presence of 100 mm EDTA,
requirement of a metal for either catalysis or structural
integrity of the protein could be confidently excluded. Kinetic
constants were determined by following the course of the
reaction by HPLC; these studies revealed a relatively low
reaction rate with a high KM (kcat= 3.63 0.3 min1, KM=
5.86 0.9 mm). Whilst this slow rate is consistent with those
reported for other) enzymes involved in secondary metabo-
lism,[16] it may also reflect the low concentration of aldehyde
present as the substrate uridine-5’-aldehyde 1 exists in
equilibrium with its hydrate form in the aqueous condition
of the enzymatic assay. In more native conditions, theKM may
be significantly lower as it is postulated that the aldehyde
substrate of Pac13 could be channelled from the previous
biosynthetic enzyme and protected from bulk solvent.
A detailed pH profile analysis demonstrated that the
enzyme was completely inactive below pH 5.4 and above
pH 10. The profile followed a bell-shaped curve (Fig-
ure S13B), with pKa1 and pKa2 values of 6.2 and 8.6,
respectively. Since the substrate does not have any ionisable
groups in this pH range, this result supports our proposal of
a histidine acting as a general base to abstract the 4’ proton.[17]
There is no obvious residue positioned to protonate the
leaving hydroxide ion and this role may be fulfilled by H42 or
by a solvent molecule mediated through E108 to eventual His
deprotonation. Though unusual, a histidine residue mediating
as a general base and acid in two sequential steps, has been
previously reported (Figure S16 and SI p. 33).[18]
To gain further confidence with regards to our proposed
mechanism, we carried out a series of site-directed muta-
genesis (SDM) studies. Mutants E108Q, K16R, H42Q, Y55F
and Y89F were produced and purified, affording diffracting
crystals of the same morphology and space group as wt Pac13,
which raised our confidence that the mutants folded correctly
and that the effects seen are specific to interactions with each
mutated residue rather than global effects on protein folding
and structure.
The mutation of H42 to a Q completely abolished activity,
further supporting our hypothesis that H42 acts as a base for
the abstraction of the 4’ proton and possibly for the proto-
nation of the 3’ hydroxy group. The kinetic measurements for
the activity of Y55F and K16R demonstrated lower affinity
and catalytic efficiency than wt Pac13 (Table 1). Mutation of
K16 to an R did not abolish activity, further demonstrating
that K16 is not an essential lysine involved in a Schiff-base
formation; hence a DHQ I-type mechanism could be further
excluded with confidence. Y89F demonstrated a significant
loss in activity compared to the wt (Table 1). Mutation of the
E108 resulted in almost no activity; a result that could
perhaps be attributed to the importance of E108 both in
stabilizing substrate binding and having a role in catalysis.
Indeed, given the open active site of Pac13, as observed in the
crystal structure, the existence of a residue that would
maintain the substrate in a productive orientation appears
to be essential. Finally, the significant loss of activity with
mutants Y89F and Y55F is consistent with their proposed
involvement in stabilizing the oxyanion and underlines their
important role for catalysis.
The biochemical data were in accordance with the data
obtained from structural analysis of the mutants. In the
H42Q–uridine complex (Figure 3A,C), the critical interac-
tions between 5’ OH and Y55 and Y89 remained the same as
in the WT-uridine structure, additionally the hydrogen bond
between K16 and E108 with 2’-OH, as well as the p-stacking
of the uracil ring with F103 are all preserved. Q42 appears to
have the same distance from the 4’ proton and the overall fold
of the protein does not seem to be impacted, all of which
suggests that the H42Q mutation affects the key catalytic step
and not substrate binding. Similarly, on examining the Y89F–
uridine complex (Figure 3B,D) and Y55F–uridine complex
structures (Figure S23, Table S4), we observed a high degree
of similarity with the wt enzyme. Although there are subtle
shifts in the position of both the ribose and uracil rings, of the
substrate, and in the orientation of the 5’ functionality, these
changes are small and consistent with our hypothesis that
decreased catalytic efficiency of these mutants is largely due
to inability of the phenyl mutants to stabilize the transient 5’
oxo-anion that forms during catalysis, rather than having
a major effect on binding competency.
This study constitutes the first structural and mechanistic
investigation into the biosynthesis of the intriguing 3’-deoxy
nucleoside moiety of the UPAs. Through a series of crystallo-
graphic and biochemical experiments, supported by SDM and
kinetics, we provide insight into the mechanism of the unique
C=C bond formation orchestrated by Pac13. We demonstrate
here that the reaction most likely proceeds via an E1Cb
mechanism, with H42 acting as an active site base, however,
unlike many other dehydratases, no metal or cofactor is
required for activity. Our deepened understanding of this
biosynthesis paves the way toward a biosynthetic alternative
to highly valuable yet, synthetically challenging 3’-modified
nucleosides. Our next goal is to further explore and challenge
Pac13 so as to develop a promising biocatalyst.
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dratase, catalyzes the formation of bio-
synthetically unique 3’-deoxyuridine,
a similar moiety to that present within
synthetic retrovirals. Structural and
mechanistic insights are reported.
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